全国药品监督管理工作会议1月6日至7日在北京召开。会议提出积极支持医药产业发展提质增效。全面 深化药品监管改革，落实对重点品种实行"提前介入、一企一策、全程指导、研审联动"的要求，支持医 药研发创新，推动中药守正创新发展，支持医疗器械高水平自立自强，促进美丽经济发展壮大。 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 渤海证券分析师侯雅楠表示，2025年我国创新药对外授权交易总金额超过1300亿美元，授权交易数量超 过150笔，创历史新高；我国在研新药管线约占全球30%，位列全球第二。我国创新药产业趋势延续， 坚定看好我国创新药产业链长期发展空间。另外，2026年JPM医疗健康大会将于1月12-15日在美国旧金 山举行，建议关注相关企业的战略布局进展，建议把握创新药、CXO及生命科学上游等相关产业链投 资机遇。 ...

证券代码：600056 证券简称：中国医药 公告编号：临2025-090号 中国医药健康产业股份有限公司 第九届董事会第34次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届董事会第34次会议（以下简称"本次会 议"）于2025年12月29日以现场结合通讯方式召开，会议由董事长、总经理杨光先生主持，公司相关高 级管理人员列席了本次会议。 (二)本次会议通知于2025年12月21日以邮件、短信、电话或传真的方式向全体董事发出。 (三)本次会议应出席董事8名，实际出席会议董事8名。 (四)本次会议的召开符合《公司法》及《公司章程》的有关规定，会议决议为有效决议。 二、会议审议情况 本次会议审议并通过如下议案： （一）审议通过了《关于收购则正医药70%股权的议案》。 经决议，董事会同意公司收购上海则正医药科技股份有限公司70%股权及签署相关协议等事项。具体内 容请详见公司在上海证券交易所网站（www.sse.com.cn）发布的临2025- ...

通过本次交易，将提升公司在医药研发创新领域的综合实力，可弥补公司当前研发体系短板，推动双方 在技术、市场和资源方面的深度融合，实现从仿制药研究、改良型新药研究到创新药研究等领域的深入 布局，并实现从研发到生产的全产业链打通，构建医药研发、医药工业和医药商业协同发展的产业布 局，有助于进一步提升上市公司的竞争力。 格隆汇12月30日丨中国医药(600056.SH)公布，为提升中国医药在医药研发创新领域的综合实力，弥补 中国医药当前的研发体系短板，打通研发到生产的全产业链，实现从仿制药研究、改良型新药研究到创 新药研究等领域的深入布局和工业企业的产品管线提升。中国医药拟签署《关于上海则正医药科技股份 有限公司之购买股份协议》，以现金方式购买贺敦伟等交易对方合计持有的则正医药70%股权。 本次交易股权转让的价格根据则正医药股东全部权益价值评估结果，经交易各方协商确定，本次交易总 金额为人民币5.25亿元。本次收购资金来源为公司自有资金和/或自筹资金。本次交易完成后，公司将 直接持有则正医药70%的股权，则正医药将成为中国医药下属控股子公司纳入公司合并报表范围。 ...

中国医药公告，公司与13名交易对方签署《关于上海则正医药科技股份有限公司之购买股份协议》，以 现金出资5.25亿元人民币购买交易对方合计所持上海则正医药科技股份有限公司70%股权。则正医药是 一家以改良型新药、复杂制剂为特色的医药研发企业，提供药品研究、临床试验、注册申报的全流程研 发服务。本次交易旨在提升中国医药在医药研发创新领域的综合实力，弥补当前研发体系短板，打通研 发到生产的全产业链。交易已获董事会审议通过，无需提交股东会审议。交易完成后，则正医药将成为 中国医药下属控股子公司。 ...

人民财讯12月13日电，12月12日，国家药监局召开党组扩大会议，会议强调，做好明年药品监管工作， 要坚持稳中求进、提质增效，着力营造公开、透明、可预期的药品监管环境，稳定药品安全形势大局， 促进医药研发创新提质增效，努力为全国经济发展大局贡献更多药监力量。一要进一步提升药品安全保 障水平，持续完善药品安全责任体系，健全常态化的药品安全风险会商机制，把风险化解在萌芽状态。 二要进一步支持医药产业高质量发展，提高审评审批质效，对重点品种实行"提前介入、一企一策、全 程指导、研审联动"，支持创新药和医疗器械发展。三要进一步促进"三医"协同发展和治理，严格按照 国际公认标准开展仿制药质量和疗效一致性评价，强化集采中选产品质量监管，支持中药传承创新发 展。四要进一步加强监管体系和能力建设，完善法规标准体系，大力发展智慧监管和监管科学，提升药 品监管现代化水平。 会议要求，要切实做好岁末年初药品监管工作，针对冬季呼吸道疾病多发态势，加强有关重点药品的监 管力度，保障节假日期间药品安全形势稳定。要有力有序抓好各项工作落实，科学谋划明年重点工作， 确保"十四五"各项工作圆满收官，实现"十五五"良好开局。 ...

Core Viewpoint - Company reported stable revenue and robust profit growth in the first half of 2025, with a focus on strengthening its position in the biopharmaceutical sector and expanding its product matrix through innovation [1][2]. Financial Performance - In the first half of 2025, the company achieved revenue of 1.239 billion yuan, essentially flat year-on-year; however, net profit attributable to shareholders increased by 6.65% to 38.81 million yuan, and net profit excluding non-recurring items rose by 36.34% to 36.85 million yuan [1]. Product Development and Sales - The strategic product, "Hydromorphone Hydrochloride Injection," saw revenue growth exceeding 90% year-on-year, becoming a key pillar for the company [2]. - The company is expanding its product line with ongoing research and development, including applications for sustained-release hydromorphone tablets and acetaminophen-hydromorphone tablets, which are currently under review [2][3]. - The company is also focusing on both formulation sales and raw material production, establishing partnerships with other pharmaceutical companies to enhance its competitive edge in the hydromorphone market [3]. Market Position and Strategy - The company has solidified its market position in traditional therapeutic areas such as cardiovascular diseases, with core products like "Benidipine Hydrochloride Tablets" capturing 55% of the market share in its category [4]. - The company has successfully expanded its market presence in non-collection markets, achieving over 20% growth in recent years for its core products [4]. - The company has also made significant strides in the OTC channel, with products like "Huasu Tablets" and "Naloxone Sublingual Tablets" receiving recognition at health conferences [5]. Regulatory Environment and Future Outlook - Recent changes in national procurement policies may benefit the company by allowing for brand-based volume reporting, which could enhance its market share in key therapeutic areas [6]. - The company is actively developing a comprehensive pain management product matrix, including new drugs and raw materials, which is expected to bolster its market position [7]. - The company has attracted attention from various investment institutions, indicating strong market recognition and potential for future growth [8].

Core Viewpoint - Longshen Rongfa (300534.SZ) reported a steady growth in revenue and net profit for the first half of 2025, demonstrating resilience in a challenging economic environment and a competitive pharmaceutical industry [1] Financial Performance - The company achieved an operating income of 496 million yuan and a net profit attributable to shareholders of 27.96 million yuan, representing a year-on-year increase of 27.48% [1] - The net profit after deducting non-recurring gains and losses reached 30.49 million yuan, up 39.93% compared to the previous year [1] Product and Market Development - Longshen Rongfa focuses on its core pharmaceutical business, enhancing its marketing system and brand building, which has led to increased hospital coverage for its key products [1] - The core products, Yuanhu Zhitong Diban and Xuanfei Zhiso Heji, covered 2,858 and 2,299 hospitals respectively, with coverage rates increasing to 19.39% and 15.56% [1] - Revenue from the drop pill products grew by 31.22% year-on-year, indicating effective market promotion [1] Product Recognition - Yuanhu Zhitong Diban and Xuanfei Zhiso Heji received multiple industry awards for their clinical efficacy and brand recognition [2] - Xuanfei Zhiso Heji ranked 7th in the "2024 China Innovative Drug Sales Enterprise Ranking (Traditional Chinese Medicine) TOP20" [2] - Yuanhu Zhitong Diban was listed among the top 20 brands in sales for traditional Chinese medicine pills in public medical institutions [2] Project Development - The company made significant progress in capacity enhancement and technology upgrades, including the acquisition of 70% of the Innovative Research Institute [3] - The production line upgrade for Xuanfei Zhiso Heji has been completed and passed GMP compliance checks, ready for production [3] - The construction and registration of a new production line for blood dialysis concentrate is underway, expected to become a new growth point [3] R&D Innovation - Longshen Rongfa established a technical center laboratory with Puan Pharmaceutical to facilitate the industrialization of R&D results [4] - Ongoing research includes real-world studies for Xuanfei Zhiso Heji and new formulations for Yuanhu Zhitong Diban [4] - The company collaborates with Lanzhou University for health food R&D, with several products launched through dual-channel marketing [4] Investor Returns and Social Responsibility - The company plans to distribute a cash dividend of 0.2 yuan per 10 shares to all shareholders for the first half of 2025 [4] - Longshen Rongfa has been recognized as a "green factory" and included in the list of high-tech, high-growth enterprises in Gansu Province [4]

Group 1 - The core viewpoint of the report is that Dongguan Securities has given a "buy" rating to Fuyuan Pharmaceutical (601089.SH) with a latest price of 30.8 yuan [2] - The reasons for the rating include a slowdown in the company's Q2 performance growth and an acceleration in the promotion of research and development innovation [2]

Core Viewpoint - Zhejiang Haisen Pharmaceutical Co., Ltd. reported a revenue increase of 14.93% in the first half of 2025, driven by strong market demand and effective sales strategies [12][22]. Financial Performance - The company achieved operating revenue of 242.09 million yuan, compared to 210.64 million yuan in the same period last year [10]. - Net profit attributable to shareholders was 59.25 million yuan, reflecting a 4.74% increase year-on-year [12]. - The basic earnings per share rose to 0.41 yuan, up 5.13% from the previous year [10]. Industry Overview - The pharmaceutical manufacturing industry is experiencing growth due to factors such as population aging, urbanization, and improved healthcare systems [9]. - The global pharmaceutical market is projected to reach 3.57 trillion doses by 2025, with China expected to lead in growth with a compound annual growth rate of 1.6% [9]. - The chemical raw materials industry is a strategic pillar of China's pharmaceutical sector, with a market size expected to exceed 740 billion yuan by 2029 [10]. Business Operations - The company specializes in the research, production, and sales of chemical pharmaceutical raw materials and intermediates, focusing on digestive, cardiovascular, and antibacterial drugs [11][19]. - The product portfolio includes high-demand items such as sucralfate and atorvastatin calcium, which have significant market shares [19][20]. - The company employs a direct sales model, ensuring close relationships with manufacturers and traders [17]. Market Position - The company is a leading manufacturer of sucralfate and atorvastatin calcium, with a strong competitive edge in both domestic and international markets [19][20]. - The company has established long-term partnerships with global clients, enhancing its market presence [21]. Research and Development - The company invested 1.77 million yuan in R&D, accounting for 7.32% of its revenue, indicating a commitment to innovation [23]. - The company has a robust pipeline of new products, with ongoing projects aimed at enhancing market competitiveness [23][24]. - A total of 25 patents have been obtained, covering various aspects of pharmaceutical production [26]. Quality Management - The company adheres to international GMP standards, ensuring high-quality production processes [27]. - A laboratory information management system (LIMS) has been implemented to enhance quality control and data integrity [27].

Group 1 - The "Xinjiang Drug Research and Innovation and Industry Exchange Seminar" was held in Urumqi, focusing on the development direction of Xinjiang's pharmaceutical innovation, with participation from various sectors including government, finance, education, technology, and medicine [1] - Xinjiang's unique traditional Chinese medicine resources are being leveraged through government support and state-owned enterprises to promote industry upgrades and establish competitive regional brands [1] - The establishment of the academician workstation led by Academician Yang Baofeng provides high-end intellectual support for drug research and development in Xinjiang [1] Group 2 - A strategic cooperation framework agreement was signed between Xinjiang Medical University and Xinjiang Financial Investment Group, focusing on talent cultivation, scientific research innovation, and market development [2] - Keynote speeches were delivered on topics such as multidisciplinary innovation in drug development and the discovery of novel drug sources from Central Asian medicinal materials [2] - Dezheng Health, a leading domestic lipid-lowering drug company, has established a comprehensive R&D system and is actively advancing multiple innovative drug projects [2] Group 3 - Dezheng Health signed a cooperation framework agreement with Academician Yang Baofeng to collaborate on drug research and development across various disease areas [3] - The newly established academician workstation will focus on small molecule drugs, peptide drugs, and non-toxic active ingredients from industrial hemp, promoting drug development and industrialization [3] - The establishment of a "Technology Innovation Development Center" aims to enhance the company's technological innovation capabilities and decision-making processes [3] Group 4 - Dezheng Health's strategic technological layout is seen as a significant milestone for the company's development, aiming to accelerate innovation and transformation in the pharmaceutical industry [4] - The collaboration with the academician workstation and expert resources will strengthen the company's internal innovation capabilities and support the advancement of its drug development pipeline [4] - This initiative is expected to inject strong momentum into the technological innovation development of Xinjiang's pharmaceutical sector [4]